Avantor (AVTR) Q3 2024 earnings summary

Executive summary

• Q3 2024 reported revenue was $1.71B, with organic revenue down 0.7% year-over-year and net income of $57.8M, a decrease from $108.4M in Q3 2023.

• Adjusted EBITDA margin was 17.6% and adjusted EPS was $0.26, both improving sequentially; adjusted net income rose to $175.2M.

• Cost transformation initiatives delivered results ahead of plan, supporting improved profitability and sequential growth in adjusted EPS.

• Successfully divested clinical services assets, netting $500M in after-tax proceeds to accelerate deleveraging.

• Advanced long-term growth strategy with new product launches, innovation center opening, and sustainability achievements.

Financial highlights

• Q3 2024 reported revenue: $1.71B; organic revenue down 0.7% year-over-year.

• Adjusted gross profit: $573M–$583M (33.4%–34.2% margin); gross margin contracted by 70 bps to 32.9%.

• Adjusted EBITDA: $302.5M–$303M (17.6% margin); adjusted operating income: $274.8M–$277M (16.0%–16.3% margin).

• Adjusted EPS: $0.26; diluted GAAP EPS: $0.08.

• Free cash flow for Q3: $204M; year-to-date free cash flow: $546.2M–$550M.

Outlook and guidance

• Raised free cash flow guidance to over $750M for the year (before $100M transformation costs).

• Full-year organic growth expected at -2% to +1%; adjusted EBITDA margin guidance: 17.3%–17.8%; adjusted EPS: $0.95–$1.03.

• Bioprocessing expected to deliver mid to high single-digit growth in Q4; Laboratory Solutions expected flat to modestly up.

• Global cost transformation initiative targets $300M in run-rate cost savings by end of 2026.

• Reported revenue guidance adjusted to $6.80B–$7.01B, reflecting Clinical Services divestiture.